Clinical Trials Logo

Hypoplasminogenemia clinical trials

View clinical trials related to Hypoplasminogenemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03642691 No longer available - Hypoplasminogenemia Clinical Trials

A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial

Start date: n/a
Phase:
Study type: Expanded Access

The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring plasminogen replacement therapy who completed the End of Study visit in the following Prometic-sponsored clinical trials: 2002C011G, 2002C013G, 2002C016G, 2002C017G and 2002C019G.

NCT ID: NCT03265171 No longer available - Hypoplasminogenemia Clinical Trials

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Start date: n/a
Phase:
Study type: Expanded Access

These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

NCT ID: NCT02690714 Completed - Hypoplasminogenemia Clinical Trials

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Start date: May 4, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3 pivotal study to evaluate pharmacokinetics (PK), efficacy, and safety of Prometic Plasminogen (Human) Intravenous Lyophilized Solution, the investigational medicinal product (IMP), in pediatric and adult subjects with hypoplasminogenemia.

NCT ID: NCT02312180 Completed - Hypoplasminogenemia Clinical Trials

A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency

Start date: December 2014
Phase: Phase 1
Study type: Interventional

ProMetic is intiitating a first-in-man study entitled "A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children with Hypoplasminogenemia". The general objectives of this clinical study, (Protocol #2002C005G), are to determine the optimal dose and interval required to support the planned Phase 2/3 study and to investigate initial safety and tolerability.